Nanjing Leads Biolabs Co., Ltd. (0DX)

Overview

Nanjing Leads Biolabs Co., Ltd. is a pioneering clinical-stage biotechnology enterprise established in 2012, with its headquarters located in Nanjing, China. The company is dedicated to the discovery, development, and commercialization of cutting-edge therapies that address significant unmet medical needs in fields such as oncology, autoimmune diseases, and other severe health conditions. With a global perspective, Nanjing Leads Biolabs is committed to improving patient outcomes through innovative solutions. The company boasts a comprehensive pipeline featuring 14 drug candidates, including six that are currently in clinical trials. This pipeline is characterized by a strong emphasis on advanced immuno-oncology concepts, particularly immuno-oncology 2.0 (IO 2.0), T-cell engagers (TCEs), and antibody-drug conjugates (ADCs). Nanjing Leads Biolabs has developed key assets that reflect its innovative spirit, notably LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB, which is currently undergoing registrational trials to treat extra-pulmonary neuroendocrine carcinoma. Another significant asset is LBL-033, a bispecific antibody targeting MUC16/CD3 for patients with gynecologic cancers. The company has pioneered proprietary platforms, such as LeadsBody™ for CD3-targeted TCEs and X-body™ for 4-1BB agonists. This innovative technology enables tailored activation of the tumor microenvironment, which helps minimize toxicity risks associated with treatments. Operating with an integrated model that spans from discovery through to pilot manufacturing, Nanjing Leads Biolabs has successfully achieved rapid IND (Investigational New Drug) submissions while establishing strategic collaborations that further expedite the development of its groundbreaking therapies. Within the pharmaceuticals and biotechnology sector, Nanjing Leads Biolabs plays a crucial role in propelling the next generation of immunotherapies aimed at treating both solid tumors and hematologic malignancies.

Products and Services

• LBL-024

  LBL-024 is a bispecific antibody that targets PD-L1 and 4-1BB, currently advancing through registrational trials. It is specifically designed to treat extra-pulmonary neuroendocrine carcinoma, representing a significant breakthrough for this patient population.

• LBL-033

  LBL-033 is a bispecific antibody targeting MUC16/CD3, aimed at treating various gynecologic cancers. This innovative approach enhances T-cell engagement with tumor cells, thereby improving treatment efficacy for patients suffering from these malignancies.

• LeadsBody™ Platform

  The LeadsBody™ platform is designed for the development of CD3-targeted T-cell engagers (TCEs). This proprietary technology facilitates a more precise targeting mechanism, thereby enhancing the therapeutic potential of T-cell engagement while reducing unintended effects.

• X-body™ Platform

  The X-body™ platform focuses on developing 4-1BB agonists, which are instrumental in the activation of T-cells within the tumor microenvironment. This platform significantly contributes to reducing the toxicity often associated with conventional immunotherapies.